Individual Patient Compassionate Use of Crenolanib
Launched by AROG PHARMACEUTICALS, INC. · Aug 7, 2018
Trial Information
Current as of June 06, 2025
Available
Keywords
ClinConnect Summary
This program is being offered on a patient by patient basis while phase 3 studies with crenolanib are ongoing.
Institutional Review Board-/Independent Ethics Committee approval must be granted before, The experimental intervention will be administered over 28-day cycles. Compassionate use of crenolanib will be limited such that it does not interfere with the supply need for phase 3 studies.
There must be adequate understanding of the indication for the requested use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject must have a serious life threatening cancer with FLT3/PDGFRa mutation or PDGFRa amplification who has exhausted all other treatment options
- • Subject and their partner (if adults) must use 2 forms of contraception during study and for 3 months following last dose of study drug
- Exclusion Criteria:
- • Subject is eligible for enrollment in an ongoing clinical trial
- • Subject has any condition which, in the investigator's opinion makes the subject unsuitable for participation
About Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with rare and aggressive hematologic malignancies. With a focus on advancing targeted treatments, Arog leverages cutting-edge research and a robust pipeline to address unmet medical needs in oncology. The company is committed to rigorous scientific exploration and collaboration, aiming to bring transformative therapies from the laboratory to clinical practice, ultimately improving patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genova, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials